. . "Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney"@en . "8"^^ . "32" . . . "Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As Y-90 emits no gamma rays, absorbed doses for Y-90 are usually estimated using the same peptide labelled with In-111. The aim of the study was to determine if replacement of Y-90/88 by In-111 affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments. Materials and Methods: Radiolabelled peptides were atministered in to male Wistar rats. Results: The peptides under studs, labelled either with In-111 or with Y-88/90 showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for Y-88/90-labeled peptide in comparison with the one of In-111. Conclusion: We conclude that a radiation-absorbed dose after Y-90-labelled somatostatin analogues appears to be lower than that predicted by the In-111-labelled peptide." . "Anticancer Research" . . . "2"^^ . "Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As Y-90 emits no gamma rays, absorbed doses for Y-90 are usually estimated using the same peptide labelled with In-111. The aim of the study was to determine if replacement of Y-90/88 by In-111 affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments. Materials and Methods: Radiolabelled peptides were atministered in to male Wistar rats. Results: The peptides under studs, labelled either with In-111 or with Y-88/90 showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for Y-88/90-labeled peptide in comparison with the one of In-111. Conclusion: We conclude that a radiation-absorbed dose after Y-90-labelled somatostatin analogues appears to be lower than that predicted by the In-111-labelled peptide."@en . . "0250-7005" . "Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney" . . "11160" . "Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney"@en . "GR - \u0158eck\u00E1 republika" . "2"^^ . . . . . "RIV/00216208:11160/12:10124209" . . "http://ar.iiarjournals.org/content/32/3/815.full" . "131248" . . . "I, P(GAP304/10/1738), P(OC08006)" . . "kidney uptake; Y-90/88; In-111; somatostatin analogue"@en . . "3" . "L\u00E1zn\u00ED\u010Dkov\u00E1, Alice" . "Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney" . "000301619200017" . . . "L\u00E1zn\u00ED\u010Dek, Milan" . "RIV/00216208:11160/12:10124209!RIV13-MSM-11160___" . "[9A43B4924D77]" . .